WDWalter Deberdt

Walter Deberdt

*This is an algorithmically generated author record based on publicly available information.

Walter Deberdt has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of ADHD in nonpsychotic adult psychiatric care (ADPSYC): A multinational cross-sectional study in Europe

    by Walter Deberdt, Johannes Thome, Jeremie Lebrec, Susanne Kraemer, Irene Fregenal, J. Antoni Ramos-Quiroga, Muhammad Arif

    Attention-deficit/hyperactivity disorder (ADHD) often persists into adulthood. This study was designed to estimate the prevalence of ADHD in adult psychiatric outpatients in several European countries. ADHD diagnosis was made using the Diagnostic Interview for ADHD in Adults, version 2.0 (DIVA), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and 5th Edition (DSM-5). Of 5662 patients present/approached, 2284 (40.3 %) consented, of whom 1986 patients (87.0 %) completed the study. Based on the DIVA, and applying DSM-IV-TR or DSM-5 criteria, 15.8 % (95 % confidence interval [CI] 14.2 %-17.4 %) or 17.4 % (95 % CI 15.7 %-19.0 %) of patients were diagnosed with ADHD, respectively. The prevalence of ADHD was 15.3 % when counting as non-ADHD those patients who screened positive but did not complete the DIVA (DSM-5). Estimates from this study indicate that a relevant part of the psychiatric outpatient care population suffers from ADHD.


  • Open Access

    Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients

    by Ilya A Lipkovich, Ernest H Choy, Peter Van Wambeke, Walter Deberdt, Doron Sagman

    To identify distinct groups of patients with fibromyalgia (FM) with respect to multiple outcome measures. Data from 631 duloxetine-treated women in 4 randomized, placebo-controlled trials were included in a cluster analysis based on outcomes after up to 12 weeks of treatment. Corresponding classification rules were constructed using a classification tree method. Probabilities for transitioning from baseline to Week 12 category were estimated for placebo and duloxetine patients (Ntotal = 1188) using logistic regression. Five clusters were identified, from “worst” (high pain levels and severe mental/physical impairment) to “best” (low pain levels and nearly normal mental/physical function). For patients with moderate overall severity, mental and physical symptoms were less correlated, resulting in 2 distinct clusters based on these 2 symptom domains. Three key variables with threshold values were identified for classification of patients: Brief Pain Inventory (BPI) pain interference overall scores of <3.29 and <7.14, respectively, a Fibromyalgia Impact Questionnaire (FIQ) interference with work score of 80% of patients were in the 3 worst categories. Duloxetine patients were significantly more likely to improve after 12 weeks than placebo patients. A sustained effect was seen with continued duloxetine treatment. FM patients are heterogeneous and can be classified into distinct subgroups by simple descriptive rules derived from only 3 variables, which may guide individual patient management. Duloxetine showed higher improvement rates than placebo and had a sustained effect beyond 12 weeks.


  • Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials

    by Angelo Camporeale, Vibeke Porsdal, Katrien De Bruyckere, Yoko Tanaka, Himanshu Upadhyaya, Claudia Deix, Walter Deberdt

    The safety profile of atomoxetine in the treatment of attention deficit hyperactivity disorder has been studied in many clinical trials. We performed an integrated safety analysis of 15 clinical trials in adults with attention deficit hyperactivity disorder. The analysis pooled patient data into three groups: acute placebo-controlled trials; long-term placebo-controlled trials; all trials. In total, 4829 adults (18–77 years, median: 36 years) were exposed to atomoxetine. Statistically significantly more atomoxetine-treated than placebo-treated patients experienced treatment-emergent adverse events (81.3% vs. 68.3% acute; 90.6% vs. 76.8% long term) and discontinued due to adverse events (8.9% vs. 4.0% acute; 17.9% vs. 6.3% long term). No statistically significant differences were observed in the proportion of patients experiencing serious adverse events. No previously unknown adverse events were identified. The most common adverse events included nausea, dry mouth, decreased appetite, insomnia and erectile dysfunction. Mean increases in heart rate (+5.2 beats per min) and blood pressure (systolic +2 mmHg, diastolic +1.9 mmHg) were modest. The proportion of patients experiencing clinically significant increases in blood pressure and heart rate at any time was statistically significantly higher with atomoxetine (systolic blood pressure 13–17%, diastolic blood pressure 37–40%, heart rate 42–43%) compared to placebo (systolic blood pressure 8–13%, diastolic blood pressure 29–34%, heart rate 21–26%). There was no increased risk of suicidal ideation or behaviour. Our findings confirm atomoxetine’s known safety profile. From a safety perspective, atomoxetine is a useful treatment option for adults with attention deficit hyperactivity disorder.


  • Open Access

    Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis

    by Joseph Peuskens, Vibeke Porsdal, Jan Pecenak, Peter Handest, Yulia D'Yachkova, Radim Brousil, Walter Deberdt

    This analysis of pooled data evaluates treatment outcomes of patients with schizophrenia receiving maintenance treatment with olanzapine long-acting injection (OLAI) by means of a categorical approach addressing the symptomatic and functional status of patients at different times. Patients were grouped into 5 categories at baseline, 6 months, and 12 months. Shifts between categories were assessed for individual patients and factors associated with improvement were analyzed. 1182 patients from 3 clinical trials were included in the current analysis. At baseline, 434 (36.8%) patients had minimal Positive and Negative Syndrome Scale (PANSS) symptoms but seriously impaired Heinrich Carpenter’s Quality of Life Scale (QLS) functioning; 303 (25.6%) had moderate to severe symptoms and seriously impaired function; 208 (17.6%) had mild to moderate symptoms but good functioning, and 162 (13.7%) had minimal symptoms and good functioning. Baseline category was significantly associated with Clinical Global Impression – Severity (CGI-S), extrapyramidal symptoms, working status, age, and number of previous episodes. The majority of all patients starting OLAI treatment maintained or improved (62% at 6 months and 52% at 12 months) their symptom and functioning levels on OLAI maintenance treatment. Less than 8% of the patients showed worsening of symptoms or functioning. An improvement in category was associated with high PANSS positive and low CGI-S scores at baseline. We present evidence that a composite assessment of schizophrenic patients including symptom severity and functioning is helpful in the evaluation of maintenance treatment outcomes. This approach could also be useful for the assessment of treatment options in clinical practice. The trials from which data are reported here were registered on clinicaltrials.gov as NCT00088491, NCT00088465, and NCT00320489.


  • Open Access

    Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

    by Ilya A Lipkovich, Walter Deberdt, John G Csernansky, Bernard Sabbe, Richard Se Keefe, Sara Kollack-Walker

    Neurocognitive impairment and psychiatric symptoms have been associated with deficits in psychosocial and occupational functioning in patients with schizophrenia. This post-hoc analysis evaluates the relationships among cognition, psychopathology, and psychosocial functioning in patients with schizophrenia at baseline and following sustained treatment with antipsychotic drugs. Data were obtained from a clinical trial assessing the cognitive effects of selected antipsychotic drugs in patients with schizophrenia. Patients were randomly assigned to 24 weeks of treatment with olanzapine (n = 159), risperidone (n = 158), or haloperidol (n = 97). Psychosocial functioning was assessed with the Heinrichs-Carpenter Quality of Life Scale [QLS], cognition with a standard battery of neurocognitive tests; and psychiatric symptoms with the Positive and Negative Syndrome Scale [PANSS]. A path-analytic approach was used to evaluate the effects of changes in cognitive functioning on subdomains of quality of life, and to determine whether such effects were direct or mediated via changes in psychiatric symptoms. At baseline, processing speed affected functioning mainly indirectly via negative symptoms. Positive symptoms also affected functioning at baseline although independent of cognition. At 24 weeks, changes in processing speed affected changes in functioning both directly and indirectly via PANSS negative subscale scores. Positive symptoms no longer contributed to the path-analytic models. Although a consistent relationship was observed between processing speed and the 3 functional domains, variation existed as to whether the paths were direct and/or indirect. Working memory and verbal memory did not significantly contribute to any of the path-analytic models studied. Processing speed demonstrated direct and indirect effects via negative symptoms on three domains of functioning as measured by the QLS at baseline and following 24 weeks of antipsychotic treatment.


  • Open Access

    Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

    by Walter Deberdt, Ilya Lipkovich, Alexandra N Heinloth, Lin Liu, Sara Kollack-Walker, Sara E Edwards, Vicki Poole Hoffmann, Thomas A Hardy

    Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing


  • Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post‐hoc analysis

    by Walter G. Deberdt, Alan Siegal, Jonna Ahl, Adam L. Meyers, Ronald Landbloom

    Objective This study was conducted to determine the effect of olanzapine treatment on cognition in elderly patients with behavioral and psychiatric symptoms (BPSD) associated with dementia. Methods This was a post‐hoc analysis of three randomized double‐blind, clinical trials of olanzapine (n = 682) vs placebo (n = 257) in dementia patients with BPSD in long‐term or continuing‐care settings. One study was 6 weeks long; the other two were 10 weeks duration, and their data were combined. Patients were subgrouped according to baseline Mini Mental State Examination (MMSE) scores: Group I = 23–26; Group II = 19–22; Group III = 14–18; Group IV = 7–13; Group V = 1–6. BPSD was assessed by the Neuropsychiatric Inventory (NPI). Results Within‐treatment group cognitive decline in patients was significant in the combined studies, but not in the 6‐week study. Between‐treatment cognitive changes were non‐significant in the 6‐week study, but showed a statistical trend in the combined studies (olanzapine, −0.78 ± 0.19 vs placebo, −0.32 ± 0.25; p = 0.06). In the subgroup analysis, there was a significant between‐treatment difference in cognitive changes in MMSE subgroup IV in the combined studies (olanzapine, −0.63 ± 0.26 vs placebo, 0.27 ± 0.41, p = 0.04). Improvement in BPSD was correlated with better cognitive outcome (r = −0.2; p < 0.01). Conclusions Although the overall differences in cognitive changes in patients treated with olanzapine vs placebo were small and non‐significant, negative effects on cognition in some patients cannot be excluded, especially in patients with more pronounced cognitive decline or whose behavioral and psychiatric symptoms are not responding to treatment. Copyright © 2007 John Wiley & Sons, Ltd.


  • Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia

    by John Kennedy, Walter Deberdt, Alan Siegal, Joseph Micca, Elisabeth Degenhardt, Jonna Ahl, Adam Meyers, Christopher Kaiser, Robert W. Baker

    Objective This was an exploratory study of olanzapine as potential treatment for improvement in cognition in patients with Alzheimer's disease without prominent psychobehavioral symptoms. Methods Non‐psychotic/non‐agitated patients (n = 268) with Alzheimer's disease, who had baseline Mini‐Mental State Examination (MMSE) scores of 14–26 were randomized to treatment with olanzapine (2.5 to 7.5 mg/d) or placebo for 26 weeks. The primary objectives were to determine if treatment with olanzapine improved cognition as indexed by the Alzheimer's disease Assessment Scale for Cognition (ADAS‐Cog) and the Clinician's Interview‐Based Impression of Change (CIBIC) after 26 weeks of therapy. Results Patients treated with olanzapine vs placebo experienced significant worsening ADAS‐Cog scores at weeks 12 (p = 0.03) and 26 (p = 0.004). Changes in CIBIC scores were not significantly different between treatment groups at either assessment. A post hoc analysis revealed that olanzapine‐treated patients with more cognitive impairment at baseline (MMSE scores of 14–18) (n = 35) experienced significantly greater deterioration in ADAS‐Cog performance than patients in the placebo group (n = 24; p < 0.001); whereas in patients with less cognitive impairment (n = 78, baseline MMSE scores of 23–26) between‐group ADAS‐Cog changes were not significant. Conclusions In this 26‐week study non‐psychotic/non‐agitated patients with Alzheimer's disease treated with olanzapine experienced significant worsening of cognition as compared to placebo. Copyright © 2005 John Wiley & Sons, Ltd.


  • Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

    by Peter Paul De Deyn, Manuel Martín Carrasco, Walter Deberdt, Claude Jeandel, Donald P Hay, Peter D Feldman, Carrie A Young, Deborah L Lehman, Alan Breier

    Objectives: Psychotic symptoms and behavioral disturbances are a concern in the care of elderly patients with Alzheimer's dementia (AD). This study was conducted to compare the efficacy of olanzapine versus placebo in patients with psychotic symptoms associated with AD in long‐term or continuing‐care settings.Methods: Patients (n = 652) with AD and delusions or hallucinations were randomly assigned to 10 weeks of double‐blind treatment with placebo or fixed‐dose olanzapine (1.0, 2.5, 5.0, 7.5 mg/day).Results: Mean age was 76.6±10.4 years. Repeated‐measures analysis showed significant improvement from baseline in NPI/NH Psychosis Total scores (sum of Delusions, Hallucinations items—primary efficacy measure) in all five treatment groups (pp = 0.008), while endpoint CGI‐C scores showed the greatest improvement in the Olz 2.5 olanzapine group (2.8 ± 1.4, p = 0.030) relative to placebo (3.2 ± 1.4). There were significant overall treatment‐group differences in increased weight, anorexia, and urinary incontinence, with olanzapine showing numerically higher incidences. However, neither the incidence of any other individual events, including extrapyramidal symptoms, nor of total adverse events occurred with significantly higher frequency in any olanzapine group relative to placebo. No clinically relevant significant changes were seen across groups in cognition or any other vital sign or laboratory measure, including glucose, triglyceride, and cholesterol.Conclusions: While 1.0 mg olanzapine did not show significant differences from placebo, the 2.5 mg dose was a reasonable starting dose. Olanzapine at 7.5 mg/day significantly decreased psychosis and overall behavioral disturbances (NPI/NH, BPRS) and was well tolerated. Copyright © 2004 John Wiley & Sons, Ltd.